Menlo Therapeutics Raises $50M

venBio leads Series C Financing of oral once-daily Anti-Pruritus Therapy in development for Pruritus of Atopic Dermatitis, Psoriasis and Prurigo Nodularis, and for Refractory Chronic Cough MENLO PARK, Calif., July 18, 2017 -- (Healthcare Sales & Marketi... Biopharmaceuticals, Venture Capital Menlo Therapeutics, Serlopitant, pruritus

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2042769

Source: HSMN NewsFeed - July 18, 2017 Category: Pharmaceuticals Source Type: news